Product Information
APTIOM 200 MG TABLET is a brand product labeled by Sumitomo Pharma America, Inc., priced at $44.2430 per EA under NDC 63402020230. Its NADAC has been published 494 times since Apr 19, 2017.
FDA first approved this application on Nov 8, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the ESLICARBAZEPINE ACETATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
200 mg/1
Manufacturer
Sumitomo Pharma America, Inc.NDC
63402020230
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
1/1/2026
Active Ingredients
ESLICARBAZEPINE ACETATEApproval Type
New Drug (NDA)
FDA Application
NDA022416FDA Approved
11/8/2013
TE Code
AB
On Market Since
4/7/2014
Pharmacological Classes
Price Statistics
The NADAC for APTIOM 200 MG TABLET has been published 494 times since Apr 19, 2017, and over the history we have for it it has risen 65.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $44.2430 per EA |
|---|---|
| All-time high | $44.2430 (Sep 30, 2026) |
| All-time low | $26.7851 (Apr 19, 2017) |
| 52-week high | $44.2430 |
| 52-week low | $42.9543 |
| Median price | $34.9948 |
| Average price | $35.5841 |
| Largest weekly change | +9.9% (Jan 10, 2018) |
| Weeks tracked | 494 |
| Tracking since | Apr 19, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ESLICARBAZEPINE ACETATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sumitomo Pharma America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ESLICARBAZEPINE ACETATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of APTIOM 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for APTIOM 200 MG TABLET, manufactured by Sumitomo Pharma America, Inc., is $44.2430 per EA (NDC 63402020230), effective Sep 30, 2026.
How has the price of APTIOM 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for APTIOM 200 MG TABLET has risen 65.2%. It has been tracked across 494 weekly CMS publications since Apr 19, 2017.
What are the highest and lowest recorded NADAC prices for APTIOM 200 MG TABLET?
Since Apr 19, 2017, the NADAC for APTIOM 200 MG TABLET has ranged from a low of $26.7851 (Apr 19, 2017) to a high of $44.2430 (Sep 30, 2026), with a median of $34.9948 per EA.
Are there cheaper alternatives to APTIOM 200 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of APTIOM 200 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures APTIOM 200 MG TABLET?
APTIOM 200 MG TABLET (NDC 63402020230) is labeled by Sumitomo Pharma America, Inc., and CMS classifies it as a brand product.